Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recall Of Millions Of Ellume COVID-19 Tests High-Risk Class I, FDA Says

It’s the second coronavirus diagnostic to be slapped with a class I recall label

Executive Summary

Ellume recalled 2,212,335 of the home tests because there’s a chance they can give false-positive results.

You may also be interested in...



Complaint Alleges Ellume Failed To Pay Refunds After Class I Recall Of OTC COVID-19 Tests

Complaint filed in Maryland federal court says Australian firm, which received more than $230 from US government to boost production of its OTC COVID-19 diagnostic tests available to US consumers, should’ve offered refunds to consumers who bought tests the company has recalled due to false positive tests.

Ellume Faces Class-Action Suit After Class I Recall Of COVID-19 Tests

The lawsuit, filed in Maryland federal court, says Ellume should’ve offered refunds to people who bought later-recalled COVID-19 tests from the company.

FDA Issues New COVID-19 EUA Requirements After HHS Restores Agency’s LDT Oversight Role

A controversial Trump-era policy that blocked the US FDA from regulating laboratory-developed tests was binned by the Health and Human Services secretary on 15 November. As a result, the FDA will once again require emergency use authorizations or other clearances for new COVID-19 tests.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT144705

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel